Normal VolunteersPhase 1NCT07205081
Safety, Tolerability and PK of ATTO-3712 in Healthy Volunteers and Patients With Atopic Dermatitis
A Phase 1 study testing ATTO-3712 in people with Normal Volunteers and Atopic Dermatitis (AD), run by Attovia Therapeutics Inc at 17 sites in 3 countries.
Trial summary
The goal of this clinical trial is to assess the safety, tolerability, and pharmacokinetics of ATTO-3712 in healthy adults and patients with atopic dermatitis. The main questions it aims to answer are: What medical problems do participants have when taking ATTO-3712? How long does ATTO-3712 stay in the body after… Read more about this study
- Who is it for?
- Ages 18 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Normal Volunteers, Atopic Dermatitis (AD), Atopic Eczema
- What is being tested?
- ATTO-3712
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 48 participants
- Where
- 17 sitesin 3 countries
- Study dates
- 22 Oct 2025to 13 Aug 2026
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Parts 1\&2 (Healthy Volunteers) Key Inclusion Criteria:
- Any sex or gender who is 18 to 65 years old, inclusive, at Screening.
- Body weight of 50 to 125 kg and body mass index (BMI) between 18.5 and 35 kg/m2
- Considered in good general health based on medical history, physical exam, 12-lead ECG, screening clinical laboratory findings, and vital signs
- Negative pregnancy test for participants of child-bearing potential.
Part 3 (Participants with Atopic Dermatitis) Key Inclusion Criteria:
- Any sex or gender who is 18 to 65 years old
- Body weight of 50 to 125 kg and BMI between 18.5 and 40 kg/m2
- Clinically confirmed diagnosis of active AD
- History of inadequate response to treatment with topical medications
- Baseline weekly mean of daily PP-NRS ≥ 4 at Day 1.
- EASI score of ≥ 16 at Screening and Day 1
- vIGA-AD score of ≥ 3 at Screening and Day 1
- ≥10% of body surface area (BSA) affected by AD at Screening and Day 1
- Use of topical bland emollient (moisturizer) at least once daily for at least 5 of the 7 days immediately before Day 1 and agrees to continue using that same emollient at the same frequency throughout the study
- Negative pregnancy test for participants of childbearing potential
Parts 1 \& 2 (Healthy Volunteers) Key Exclusion Criteria
- Any clinically significant underlying illness
- History of malignancy within 5 years of Screening
- History of major surgery within 8 weeks prior to Day 1 or has a major surgery planned during the study
- History of uncontrolled asthma requiring rescue treatment with a bronchodilator for an increase in symptoms more than twice per week
- History of hypersensitivity (including anaphylaxis) to a biologic medication, vaccine, an immunoglobulin product (plasma-derived or recombinant, eg, monoclonal antibody), or to any of the IP excipients (sucrose, polysorbate 80, or histidine)
- Active hepatitis B virus (HBV) or hepatitis C virus (HCV) or is positive for HIV
- Active or latent tuberculosis infection
- Smoking more than 20 cigarettes (or cigars, cigarillos, or e-cigarettes equivalent) per day
- History of drug or alcohol abuse
- Laboratory values outside of the normal range
Part 3 (Participants with Atopic Dermatitis) Key Exclusion Criteria:
- Any clinically significant underlying illness
- Presence of skin comorbidities that may interfere with study assessments
- Has taken prescription medication for the treatment of AD or other prohibited medication within the restricted time limits (defined in the protocol)
- Has applied topical corticosteroids within 2 weeks prior to dosing.
- History of malignancy within 5 years of Screening
- History of major surgery within 8 weeks prior to Day 1 or has a major surgery planned during the study
- History of uncontrolled asthma requiring rescue treatment with a bronchodilator for an increase in symptoms more than twice per week
- History of recurrent eczema herpeticum
- History of known primary immunodeficiency, is considered immunocompromised, history of untreated latent tuberculosis infection, has been treated for active tuberculosis in the past year, or has been treated for a parasitic infection in the past 6 months
- History of major depression
- History of hypersensitivity (including anaphylaxis) to a biologic medication, vaccine, an immunoglobulin product (plasma-derived or recombinant, eg, monoclonal antibody), or to any of the IP excipients (sucrose, polysorbate 80, or histidine)
- Participant has experienced significant flare(s) in AD in the 2 weeks prior to Screening or during the Screening period
- EASI score for the participant has more than doubled between Screening and Day 1
- Active HBV or HCV or is positive for HIV
- Participant is smoking more than 20 cigarettes (or cigars, cigarillos, or e-cigarettes equivalent to approximately 40 mg nicotine) per day
- Participant has an ECG with a QTcF > 450 msec for males or > 470 msec for females at Screening
- History of drug or alcohol abuse
- Laboratory values outside of the normal range
Trial locations and contacts
17 sites in 3 countries.
17 sites in 3 countries
United States9 sites
Attovia Clinical Site 208
Coral Gables, Florida, 33134
Attovia Clinical Site 203
Encinitas, California, 92024
Attovia Clinical Site 209
Fountain Valley, California, 92708
Attovia Clinical Site 205
Huntington Beach, California, 92647
Attovia Clinical Site 206
Indianapolis, Indiana, 46250
Attovia Clinical Site 210
New York, New York, 10128
Attovia Clinical Site 204
Rocklin, California, 95765
Attovia Clinical Site 202
Saint Joseph, Missouri, 64506
Attovia Clinical Site 207
Sweetwater, Florida, 33172
New Zealand6 sites
Attovia Clinical Site 301
Auckland, Auckland, 1010
Attovia Clinical Site 306
Auckland, NZ, 0626
Attovia Clinical Site 304
Christchurch, NZ, 8000
Attovia Clinical Site 302
Hamilton, NZ, 3204
Attovia Clinical Site 303
Nelson, NZ, 7011
Attovia Clinical Site 305
Wellington, NZ, 6021
Canada2 sites
Altasciences
Montreal, Quebec, H3P 3P1
Attovia Clinical Site 102
Peterborough, Ontario, K9J 5K2
About this study
Official title: A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multi-Part, Single Ascending Dose and Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of ATTO-3712 in Healthy Adult Volunteers and Patients With Atopic Dermatitis
The goal of this clinical trial is to assess the safety, tolerability, and pharmacokinetics of ATTO-3712 in healthy adults and patients with atopic dermatitis.
The main questions it aims to answer are:
What medical problems do participants have when taking ATTO-3712? How long does ATTO-3712 stay in the body after dosing? Researchers will compare ATTO-3712 to a placebo (a look-alike substance that contains no drug).
Participants will be dosed with ATTO-3712 or a placebo, visit the clinic for checkups and tests, and keep a diary of their symptoms.
Read the detailed description
This is a 3-part study. Parts 1 and 2 will be a single and multiple ascending dose design, respectively, assessing the safety, tolerability, and PK of ATTO-3712 in healthy adult volunteers. Part 3 will consist of multiple doses in adult patients with atopic dermatitis to assess safety, tolerability, PK, and PD based on biomarkers in the blood.
- Conditions
- Normal Volunteers, Atopic Dermatitis (AD), Atopic Eczema, Atopic Eczema/Dermatitis (Non-Specific)
- Being tested
- ATTO-3712, Placebo
- Keywords
- Atopic Dermatitis, AD, Atopic Eczema, Ecema, Itch, Pruritus
- Medical subject headings
- Dermatitis, Atopic, Dermatitis, Pruritus
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ATTO-3712Drug
ATTO-3712
PlaceboDrug
Placebo preparation to match ATTO-3712 dose
| Study group | Role | What they receive |
|---|---|---|
| ATTO-3712 single dose IV | Experimental | ATTO-3712 Dose level cohorts receiving a single dose IV Receives: Drug: ATTO-3712 |
| Placebo single dose IV | Placebo comparator | Placebo preparation to match Experimental Arm with single dose IV Receives: Drug: Placebo |
| ATTO-3712 single dose SC | Experimental | ATTO-3712 dose level cohorts receiving a single dose SC Receives: Drug: ATTO-3712 |
| Placebo single dose SC | Placebo comparator | Placebo preparation to match Experimental Arm with single dose SC Receives: Drug: Placebo |
| ATTO-3712 multiple dose SC | Experimental | ATTO-3712 administered to dose level cohorts in multiple SC doses Receives: Drug: ATTO-3712 |
| Placebo multiple dose SC | Placebo comparator | Placebo preparation to match Experimental Arm administered in multiple SC doses Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence of AEs
The primary analysis will describe the incidence of AEs and laboratory abnormalities. AEs will be coded according to system organ class and preferred term using the Medical Dictionary for Regulatory Activities (MedDRA, version 28.0 or the current version). Their severity will be graded using the NCI CTCAE v5.0 or the current version.
Measured: 0-113 Days for SAD; 0-143 Days for MAD
Incidence of laboratory abnormalities
Clinical laboratory parameters (hematologic and blood chemistry) will be summarized by visit
Measured: 0-113 Days for SAD; 0-143 days for MAD
Incidence of ECG abnormalities
ECG findings (including QT abnormalities) will be summarized by visit.
Measured: 0-113 Days for SAD; 0-143 Days for MAD
Incidence of vital sign abnormalities
Vital signs (systolic and diastolic blood pressure, temperature, heart rate) will be summarized by visit.
Measured: 0-113 Days for SAD; 0-143 Days for MAD
Secondary outcomes (7)
Incidence of Anti-Drug Antibodies
Baseline prevelance of ADA, changes in ADA status from prior to the first dose of IP to each applicable post-dose timepoint and ADA titer values for samples confirmed positive for ADA will be evaluated to assess the immunogenicity of single and multiple dose levels of ATT-3712.
Measured: 0-113 Days for SAD; 0-143 Days for MAD
Peak plasma concentration (Cmax) ATTO-3712
The pharmacokinetics of single and multiple dose levels of ATTO-3712 in participants will include maximum concentration (Cmax) of ATTO-3712
Measured: 0-113 Days for SAD; 0-143 Days for MAD
Circulating half-life of ATTO-3712 (t1/2)
The pharmacokinetics of single and multiple dose levels of ATTO-3712 in participants will include half-life (t1/2) of ATTO-3712.
Measured: 0-113 Days for SAD; 0-143 Days for MAD
Area Under the Plasma Concentration Versus Time Curve (AUC)
The pharmacokinetics of single and multiple dose levels of ATTO-3712 in participants will include area under the plasma concentration-time curve (AUC).
Measured: 0-113 Days for SAD; 0-143 Days for MAD
Clearance Rate (C) of ATTO-3712
The pharmacokinetics of single and multiple dose levels of ATTO-3712 in participants will include characterization of the clearance rate (C) of ATTO-3712.
Measured: 0-113 Days for SAD; 0-143 Days for MAD
Volume of Distribution (V) of ATTO-3712
The pharmacokinetics of single and multiple dose levels of ATTO-3712 in participants will include characterization of the Volume of distribution (V) of ATTO-3712.
Measured: 0-113 Days for SAD; 0-143 Days for MAD
Bioavailability (F) of ATTO-3712
The pharmacokinetics of single and multiple dose levels of ATTO-3712 in participants will include characterization of the Bioavailability (F) of ATTO-3712.
Measured: 0-113 Days for SAD; 0-143 Days for MAD
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Oct 2025
- Study start22 Oct 2025
- Primary completion13 Aug 2026
- Study completion13 Aug 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Normal VolunteersStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Sequential
- Model description
- Single ascending dose, multiple ascending dose, randomized, double-blind, placebo-controlled
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 48 participants (actual)
Sponsor and investigators
- Lead sponsor
- Attovia Therapeutics Inc
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07205081
- Sponsor's protocol ID
- ATTO-3712-101
- Status last verified
- Sep 2026
- First submitted
- 24 Sep 2025
- Last updated
- 11 Sep 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 11 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multi-Part, Single Ascending Dose and Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of ATTO-3712 in Healthy Adult Volunteers and Patients With Atopic Dermatitis
- ClinicalTrials.gov ID
- NCT07205081
- Acronym / sponsor ID
- ATTO-3712-101
- Conditions
- Normal Volunteers, Atopic Dermatitis (AD), Atopic Eczema, Atopic Eczema/Dermatitis (Non-Specific)
- Keywords
- Atopic Dermatitis, AD, Atopic Eczema, Ecema, Itch, Pruritus
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 48 participants (actual)
- Lead sponsor
- Attovia Therapeutics IncIndustry (pharma, biotech, devices)
- Study start
- 22 Oct 2025 (actual)
- Primary completion
- 13 Aug 2026 (actual)
- Study completion
- 13 Aug 2026 (actual)
- First posted
- 3 Oct 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to assess the safety, tolerability, and pharmacokinetics of ATTO-3712 in healthy adults and patients with atopic dermatitis.
The main questions it aims to answer are:
What medical problems do participants have when taking ATTO-3712? How long does ATTO-3712 stay in the body after dosing? Researchers will compare ATTO-3712 to a placebo (a look-alike substance that contains no drug).
Participants will be dosed with ATTO-3712 or a placebo, visit the clinic for checkups and tests, and keep a diary of their symptoms.
Detailed description
This is a 3-part study. Parts 1 and 2 will be a single and multiple ascending dose design, respectively, assessing the safety, tolerability, and PK of ATTO-3712 in healthy adult volunteers. Part 3 will consist of multiple doses in adult patients with atopic dermatitis to assess safety, tolerability, PK, and PD based on biomarkers in the blood.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Sequential
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 6
- Model description
- Single ascending dose, multiple ascending dose, randomized, double-blind, placebo-controlled
| Arm | Type | Receives |
|---|---|---|
| ATTO-3712 single dose IV | Experimental | Drug: ATTO-3712ATTO-3712 Dose level cohorts receiving a single dose IV |
| Placebo single dose IV | Placebo comparator | Drug: PlaceboPlacebo preparation to match Experimental Arm with single dose IV |
| ATTO-3712 single dose SC | Experimental | Drug: ATTO-3712ATTO-3712 dose level cohorts receiving a single dose SC |
| Placebo single dose SC | Placebo comparator | Drug: PlaceboPlacebo preparation to match Experimental Arm with single dose SC |
| ATTO-3712 multiple dose SC | Experimental | Drug: ATTO-3712ATTO-3712 administered to dose level cohorts in multiple SC doses |
| Placebo multiple dose SC | Placebo comparator | Drug: PlaceboPlacebo preparation to match Experimental Arm administered in multiple SC doses |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ATTO-3712ATTO-3712 | Drug | ATTO-3712 multiple dose SC, ATTO-3712 single dose IV, ATTO-3712 single dose SC |
| PlaceboPlacebo preparation to match ATTO-3712 dose | Drug | Placebo multiple dose SC, Placebo single dose IV, Placebo single dose SC |
Primary outcome
Incidence of AEs
Time frame: 0-113 Days for SAD; 0-143 Days for MAD
The primary analysis will describe the incidence of AEs and laboratory abnormalities. AEs will be coded according to system organ class and preferred term using the Medical Dictionary for Regulatory Activities (MedDRA, version 28.0 or the current version). Their severity will be graded using the NCI CTCAE v5.0 or the current version.
Incidence of laboratory abnormalities
Time frame: 0-113 Days for SAD; 0-143 days for MAD
Clinical laboratory parameters (hematologic and blood chemistry) will be summarized by visit
Incidence of ECG abnormalities
Time frame: 0-113 Days for SAD; 0-143 Days for MAD
ECG findings (including QT abnormalities) will be summarized by visit.
Incidence of vital sign abnormalities
Time frame: 0-113 Days for SAD; 0-143 Days for MAD
Vital signs (systolic and diastolic blood pressure, temperature, heart rate) will be summarized by visit.
7 secondary outcomes
Incidence of Anti-Drug Antibodies
Time frame: 0-113 Days for SAD; 0-143 Days for MAD
Peak plasma concentration (Cmax) ATTO-3712
Time frame: 0-113 Days for SAD; 0-143 Days for MAD
Circulating half-life of ATTO-3712 (t1/2)
Time frame: 0-113 Days for SAD; 0-143 Days for MAD
Area Under the Plasma Concentration Versus Time Curve (AUC)
Time frame: 0-113 Days for SAD; 0-143 Days for MAD
Clearance Rate (C) of ATTO-3712
Time frame: 0-113 Days for SAD; 0-143 Days for MAD
Volume of Distribution (V) of ATTO-3712
Time frame: 0-113 Days for SAD; 0-143 Days for MAD
Bioavailability (F) of ATTO-3712
Time frame: 0-113 Days for SAD; 0-143 Days for MAD
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Sep 2026.
- Individual participant dataSharing planned: No
Related trials for Normal Volunteers
RecruitingPhase 1
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
Healthy Volunteer, Atopic Dermatitis
RecruitingObservational study
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
Graft-Versus-Host Disease, Graft-versus-leukemia
RecruitingPhase 1
A Study of HB0017 Injection in Healthy Volunteers to Evaluate Safety and Tolerability of a Single Subcutaneous Injection in Low-Body-Weight Subjects; and Pharmacokinetics at Different Subcutaneous Injection Sites at the Same Dose
Psoriasis, Ankylosing Spondylitis
Not yet recruitingPhase 2
Effects of Meal Macronutrients on Postprandial Lipids
Nephrotic Syndrome, Lipodystrophy
RecruitingPhase 2
Effects of Treatments on Atopic Dermatitis
Eczema, Dermatitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
17 sites in 3 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing ATTO-3712 in people with Normal Volunteers and Atopic Dermatitis (AD), run by Attovia Therapeutics Inc at 17 sites in 3 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 11 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 17 sites in United States, New Zealand, Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence of AEs (time frame: 0-113 Days for SAD; 0-143 Days for MAD). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Sep 2026.